Bruno Bockorny

Abstract CT232: Preliminary results of a phase 1, first-in-human, dose-escalation study of the anti-CCR8 antibody denikitug in participants with advanced solid tumors

Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial

A large-scale proteomics resource of circulating extracellular vesicles for biomarker discovery in pancreatic cancer

LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)

Facts and Hopes in Immunotherapy of Pancreatic Cancer

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

PDX-derived organoids model in vivo drug response and secrete biomarkers

OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models

A Multi-Center Phase IIA Trial to Assess the Safety and Efficacy of BL-8040 (a CXCR4 Inhibitor) in Combination with Pembrolizumab and Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC)

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression

Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score